Reasons for medication non-initiation: A qualitative exploration of the patients' perspective.

Medication adherence Primary care Qualitative research Shared-decision making

Journal

Research in social & administrative pharmacy : RSAP
ISSN: 1934-8150
Titre abrégé: Res Social Adm Pharm
Pays: United States
ID NLM: 101231974

Informations de publication

Date de publication:
05 2020
Historique:
received: 22 01 2019
revised: 25 07 2019
accepted: 01 08 2019
pubmed: 14 8 2019
medline: 15 7 2021
entrez: 13 8 2019
Statut: ppublish

Résumé

Non-initiation occurs when the doctor prescribes a new pharmacological treatment to a patient who does not fill the prescription. Non-initiation prevalence estimates range between 6% and 28% in Primary Care (PC) and it is associated with poorer clinical outcomes, more sick-leave days and higher costs. To date, the reasons for non-initiation have not been explored using a qualitative framework. The aim of the present study was to identify reasons for medication non-initiation among PC patients with distinct treatment profiles (acute, chronic symptomatic and asymptomatic, and mental disorders). An exploratory, explanatory qualitative study based on Grounded Theory. We conducted individual semi-structured interviews with 30 PC patients. A constant comparative method of analysis was performed. The results were similar for all therapeutic groups. The decision to initiate treatment is multifactorial. Users make a risk-benefit assessment which is influenced by their beliefs about the pathology and the medication, their emotional reaction, health literacy and cultural factors. The patients' context and relationship with the health system influence decision-making. The decision to initiate a treatment is strongly influenced by factors that health professionals can discuss with patients. Health professionals should explore patients' beliefs about benefits and risks to help them make informed decisions and promote shared decision-making. General practitioners should ensure that patients understand the benefits and risks of disease and treatment, while explaining alternative treatments, encouraging patients to ask questions and supporting their treatment decisions.

Sections du résumé

BACKGROUND
Non-initiation occurs when the doctor prescribes a new pharmacological treatment to a patient who does not fill the prescription. Non-initiation prevalence estimates range between 6% and 28% in Primary Care (PC) and it is associated with poorer clinical outcomes, more sick-leave days and higher costs. To date, the reasons for non-initiation have not been explored using a qualitative framework.
OBJECTIVE
The aim of the present study was to identify reasons for medication non-initiation among PC patients with distinct treatment profiles (acute, chronic symptomatic and asymptomatic, and mental disorders).
METHODS
An exploratory, explanatory qualitative study based on Grounded Theory. We conducted individual semi-structured interviews with 30 PC patients. A constant comparative method of analysis was performed.
RESULTS
The results were similar for all therapeutic groups. The decision to initiate treatment is multifactorial. Users make a risk-benefit assessment which is influenced by their beliefs about the pathology and the medication, their emotional reaction, health literacy and cultural factors. The patients' context and relationship with the health system influence decision-making.
CONCLUSIONS
The decision to initiate a treatment is strongly influenced by factors that health professionals can discuss with patients. Health professionals should explore patients' beliefs about benefits and risks to help them make informed decisions and promote shared decision-making. General practitioners should ensure that patients understand the benefits and risks of disease and treatment, while explaining alternative treatments, encouraging patients to ask questions and supporting their treatment decisions.

Identifiants

pubmed: 31402307
pii: S1551-7411(19)30059-2
doi: 10.1016/j.sapharm.2019.08.002
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

663-672

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

M Gil-Girbau (M)

Research and Development Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Catalonia, Spain; School of Pharmacy, University of Barcelona, Barcelona, Catalonia, Spain; Primary Care Prevention and Health Promotion Research Network (REDIAPP), Barcelona, Catalonia, Spain.

I Aznar-Lou (I)

Research and Development Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Catalonia, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Madrid, Spain.

M T Peñarrubia-María (MT)

Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Madrid, Spain; Catalan Institute of Health, Barcelona, Spain; Primary Care Research Institute (IDIAP Jordi Gol), Barcelona, Spain.

P Moreno-Peral (P)

Primary Care Prevention and Health Promotion Research Network (REDIAPP), Barcelona, Catalonia, Spain; Málaga-Guadalhorce Primary Care Disctrict, Málaga, Spain; Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain.

A Fernández (A)

Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Madrid, Spain; Service of Community Health, Public Health Agency of Barcelona, Barcelona, Spain.

J Á Bellón (JÁ)

Primary Care Prevention and Health Promotion Research Network (REDIAPP), Barcelona, Catalonia, Spain; Málaga-Guadalhorce Primary Care Disctrict, Málaga, Spain; Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain; El Palo Health Center, Andalusian Health Service (SAS), Málaga, Spain.

A M Jové (AM)

Catalan Institute of Health, Barcelona, Spain; Primary Care Research Institute (IDIAP Jordi Gol), Barcelona, Spain.

J Mendive (J)

Primary Care Prevention and Health Promotion Research Network (REDIAPP), Barcelona, Catalonia, Spain; Catalan Institute of Health, Barcelona, Spain; Primary Care Research Institute (IDIAP Jordi Gol), Barcelona, Spain.

R Fernández-Vergel (R)

Primary Care Prevention and Health Promotion Research Network (REDIAPP), Barcelona, Catalonia, Spain; Catalan Institute of Health, Barcelona, Spain; Primary Care Research Institute (IDIAP Jordi Gol), Barcelona, Spain.

A Figueiras (A)

Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Madrid, Spain; Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain; Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

M March-Pujol (M)

School of Pharmacy, University of Barcelona, Barcelona, Catalonia, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Madrid, Spain.

M Rubio-Valera (M)

Research and Development Unit, Institut de Recerca Sant Joan de Déu, Barcelona, Catalonia, Spain; School of Pharmacy, University of Barcelona, Barcelona, Catalonia, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología y Salud Pública - CIBERESP), Madrid, Spain. Electronic address: mrubio@pssjd.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH